NON-pharmacological Approach Less Invasive Surfactant Administration (NONA-LISA) trial : protocol for a randomised controlled trial
© 2024. The Author(s)..
INTRODUCTION: Using pre-procedure analgesia with the risk of apnoea may complicate the Less Invasive Surfactant Administration (LISA) procedure or reduce the effect of LISA.
METHODS: The NONA-LISA trial (ClinicalTrials.gov, NCT05609877) is a multicentre, blinded, randomised controlled trial aiming at including 324 infants born before 30 gestational weeks, meeting the criteria for surfactant treatment by LISA. Infants will be randomised to LISA after administration of fentanyl 0.5-1 mcg/kg intravenously (fentanyl group) or isotonic saline solution intravenously (saline group). All infants will receive standardised non-pharmacological comfort care before and during the LISA procedure. Additional analgesics will be provided at the clinician's discretion. The primary outcome is the need for invasive ventilation, meaning mechanical or manual ventilation via an endotracheal tube, for at least 30 min (cumulated) within 24 h of the procedure. Secondary outcomes include the modified COMFORTneo score during the procedure, bronchopulmonary dysplasia at 36 weeks, and mortality at 36 weeks.
DISCUSSION: The NONA-LISA trial has the potential to provide evidence for a standardised approach to relief from discomfort in preterm infants during LISA and to reduce invasive ventilation. The results may affect future clinical practice.
IMPACT: Pre-procedure analgesia is associated with apnoea and may complicate procedures that rely on regular spontaneous breathing, such as Less Invasive Surfactant Administration (LISA). This randomised controlled trial addresses the effect of analgesic premedication in LISA by comparing fentanyl with a placebo (isotonic saline) in infants undergoing the LISA procedure. All infants will receive standardised non-pharmacological comfort. The NONA-LISA trial has the potential to provide evidence for a standardised approach to relief from discomfort or pain in preterm infants during LISA and to reduce invasive ventilation. The results may affect future clinical practice regarding analgesic treatment associated with the LISA procedure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Pediatric research - (2024) vom: 11. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Breindahl, Niklas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.01.2024 published: Print-Electronic ClinicalTrials.gov: NCT05609877 Citation Status Publisher |
|---|
| doi: |
10.1038/s41390-023-02998-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366909126 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366909126 | ||
| 003 | DE-627 | ||
| 005 | 20240114234019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41390-023-02998-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM366909126 | ||
| 035 | |a (NLM)38200325 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Breindahl, Niklas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NON-pharmacological Approach Less Invasive Surfactant Administration (NONA-LISA) trial |b protocol for a randomised controlled trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05609877 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a INTRODUCTION: Using pre-procedure analgesia with the risk of apnoea may complicate the Less Invasive Surfactant Administration (LISA) procedure or reduce the effect of LISA | ||
| 520 | |a METHODS: The NONA-LISA trial (ClinicalTrials.gov, NCT05609877) is a multicentre, blinded, randomised controlled trial aiming at including 324 infants born before 30 gestational weeks, meeting the criteria for surfactant treatment by LISA. Infants will be randomised to LISA after administration of fentanyl 0.5-1 mcg/kg intravenously (fentanyl group) or isotonic saline solution intravenously (saline group). All infants will receive standardised non-pharmacological comfort care before and during the LISA procedure. Additional analgesics will be provided at the clinician's discretion. The primary outcome is the need for invasive ventilation, meaning mechanical or manual ventilation via an endotracheal tube, for at least 30 min (cumulated) within 24 h of the procedure. Secondary outcomes include the modified COMFORTneo score during the procedure, bronchopulmonary dysplasia at 36 weeks, and mortality at 36 weeks | ||
| 520 | |a DISCUSSION: The NONA-LISA trial has the potential to provide evidence for a standardised approach to relief from discomfort in preterm infants during LISA and to reduce invasive ventilation. The results may affect future clinical practice | ||
| 520 | |a IMPACT: Pre-procedure analgesia is associated with apnoea and may complicate procedures that rely on regular spontaneous breathing, such as Less Invasive Surfactant Administration (LISA). This randomised controlled trial addresses the effect of analgesic premedication in LISA by comparing fentanyl with a placebo (isotonic saline) in infants undergoing the LISA procedure. All infants will receive standardised non-pharmacological comfort. The NONA-LISA trial has the potential to provide evidence for a standardised approach to relief from discomfort or pain in preterm infants during LISA and to reduce invasive ventilation. The results may affect future clinical practice regarding analgesic treatment associated with the LISA procedure | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Henriksen, Tine Brink |e verfasserin |4 aut | |
| 700 | 1 | |a Heiring, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Bay, Emma Therese |e verfasserin |4 aut | |
| 700 | 1 | |a Haaber, Jannie |e verfasserin |4 aut | |
| 700 | 1 | |a Salmonsen, Tenna Gladbo |e verfasserin |4 aut | |
| 700 | 1 | |a Carlsen, Emma Louise Malchau |e verfasserin |4 aut | |
| 700 | 1 | |a Zachariassen, Gitte |e verfasserin |4 aut | |
| 700 | 1 | |a Agergaard, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Viuff, Anne-Cathrine Finnemann |e verfasserin |4 aut | |
| 700 | 1 | |a Bender, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Grønnebæk Tolsgaard, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Aunsholt, Lise |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric research |d 1967 |g (2024) vom: 11. Jan. |w (DE-627)NLM000008672 |x 1530-0447 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41390-023-02998-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 01 | ||